

# Mikhail N Kosiborod

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4191781/mikhail-n-kosiborod-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

265  
papers

17,917  
citations

62  
h-index

129  
g-index

322  
ext. papers

24,099  
ext. citations

9.7  
avg, IF

6.6  
L-index

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 265 | Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1995-2008   | 59.2 | 2021      |
| 264 | Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , <b>2018</b> , 392, 1519-1529  | 40   | 771       |
| 263 | Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 16-38  | 5.6  | 737       |
| 262 | Excess Mortality among Persons with Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1720-1728  | 59.2 | 562       |
| 261 | Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). <i>Circulation</i> , <b>2017</b> , 136, 249-259  | 16.7 | 519       |
| 260 | Glycemic control and excess mortality in type 1 diabetes. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1972-82   | 59.2 | 513       |
| 259 | Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. <i>Diabetes Care</i> , <b>2009</b> , 32, 187-92                                  | 14.6 | 500       |
| 258 | Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 303, 2141-7   | 27.4 | 485       |
| 257 | Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. <i>Circulation</i> , <b>2005</b> , 111, 3078-86  | 16.7 | 472       |
| 256 | Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 1-9  | 5    | 315       |
| 255 | Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. <i>Circulation</i> , <b>2008</b> , 117, 1610-9   | 16.7 | 308       |
| 254 | Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. <i>Circulation</i> , <b>2008</b> , 117, 1018-27  | 16.7 | 290       |
| 253 | Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?. <i>Journal of Cardiac Failure</i> , <b>2003</b> , 9, 13-25   | 3.3  | 279       |
| 252 | Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 298-304 | 15.1 | 272       |
| 251 | Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. <i>Diabetes Care</i> , <b>2015</b> , 38, 1777-803   | 14.6 | 271       |
| 250 | Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. <i>Circulation</i> , <b>2009</b> , 119, 351-7                                    | 16.7 | 265       |
| 249 | Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 2628-2639   | 15.1 | 263       |

|     |   |      |     |
|-----|---|------|-----|
| 248 | Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 301, 1556-64  | 27.4 | 246 |
| 247 | Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 129-139   | 59.2 | 243 |
| 246 | Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. <i>Circulation</i> , <b>2015</b> , 132, 691-718   | 16.7 | 239 |
| 245 | Hospital-wide code rates and mortality before and after implementation of a rapid response team. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 300, 2506-13   | 27.4 | 230 |
| 244 | Serum potassium levels and mortality in acute myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 307, 157-64  | 27.4 | 223 |
| 243 | Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 2223-33   | 27.4 | 222 |
| 242 | The prognostic importance of anemia in patients with heart failure. <i>American Journal of Medicine</i> , <b>2003</b> , 114, 112-9  | 2.4  | 221 |
| 241 | 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 2000-2022  | 15.1 | 180 |
| 240 | Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. <i>Circulation</i> , <b>2019</b> , 140, e294-e324   | 16.7 | 168 |
| 239 | ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to develop performance measures for ST-elevation and non-ST-elevation myocardial infarction). <i>Circulation</i> , <b>2008</b> , 118, 2596-608   | 16.7 | 167 |
| 238 | Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , <b>2016</b> , 134, e535-e578   | 16.7 | 164 |
| 237 | Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. <i>Circulation</i> , <b>2019</b> , 140, 1463-1476  | 16.7 | 163 |
| 236 | Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. <i>Kidney International</i> , <b>2018</b> , 94, 26-39  | 16.7 | 160 |
| 235 | Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 1353-1368  | 27.4 | 155 |
| 234 | ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American Academy of Family Physicians and the American College of Emergency Physicians. Endorsed by the American Association of Cardiovascular and Pulmonary Nurses. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 2046-59 | 15.1 | 152 |
| 233 | Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 2038-45   | 15.1 | 150 |
| 232 | A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 665-675  | 12.3 | 145 |
| 231 | Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. <i>Circulation</i> , <b>2020</b> , 141, 90-99   | 16.7 | 130 |

|     |   |      |     |
|-----|---|------|-----|
| 230 | 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 1117-1145 | 15.1 | 124 |
| 229 | Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath-PCI Registry. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3, e001380                       | 6    | 114 |
| 228 | Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments. <i>Circulation</i> , <b>2007</b> , 115, 1975-81  | 16.7 | 114 |
| 227 | Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 27-35   | 18.1 | 109 |
| 226 | Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , <b>2019</b> , 394, 1169-1180  | 40   | 106 |
| 225 | The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1402-1411   | 12.3 | 103 |
| 224 | Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1050-6   | 12.3 | 98  |
| 223 | Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. <i>Circulation</i> , <b>2009</b> , 119, 1899-907  | 16.7 | 97  |
| 222 | Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. <i>Archives of Internal Medicine</i> , <b>2005</b> , 165, 2237-44   |      | 95  |
| 221 | Glucose normalization and outcomes in patients with acute myocardial infarction. <i>Archives of Internal Medicine</i> , <b>2009</b> , 169, 438-46   |      | 88  |
| 220 | Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. <i>Circulation</i> , <b>2008</b> , 118, 2139-45  | 16.7 | 86  |
| 219 | Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , <b>2020</b> , 41, 2379-2392  | 9.5  | 80  |
| 218 | Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 667-671                             | 6.7  | 78  |
| 217 | Utility estimates for decision-analytic modeling in chronic heart failure--health states based on New York Heart Association classes and number of rehospitalizations. <i>Value in Health</i> , <b>2009</b> , 12, 185-7   | 3.3  | 77  |
| 216 | Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. <i>Diabetes Care</i> , <b>2005</b> , 28, 1680-9   | 14.6 | 77  |
| 215 | Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. <i>Circulation</i> , <b>2018</b> , 138, 1904-1907   | 16.7 | 75  |
| 214 | Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR Research to Practice project. <i>European Journal of Preventive Cardiology</i> , <b>2017</b> , 24, 1637-1645  | 3.9  | 73  |
| 213 | Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). <i>Cardiovascular Diabetology</i> , <b>2018</b> , 17, 150  | 8.7  | 73  |

|     |  |      |    |
|-----|--|------|----|
| 212 | Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. <i>Pharmacological Research</i> , <b>2016</b> , 113, 585-591  | 10.2 | 72 |
| 211 | Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 1433-40  | 15.1 | 71 |
| 210 | Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2014</b> , 7, 844-50   | 5.8  | 70 |
| 209 | Changes in outcomes for internal medicine inpatients after work-hour regulations. <i>Annals of Internal Medicine</i> , <b>2007</b> , 147, 97-103   | 8    | 69 |
| 208 | Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. <i>Circulation</i> , <b>2021</b> , 143, 298-309  | 16.7 | 69 |
| 207 | Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. <i>Circulation</i> , <b>2020</b> , 141, 100-111  | 16.7 | 68 |
| 206 | SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 2497-2506   | 15.1 | 68 |
| 205 | Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2019</b> , 14, 798-809   | 6.9  | 64 |
| 204 | Incidence, correlates, and outcomes of acute, hospital-acquired anemia in patients with acute myocardial infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2010</b> , 3, 337-46   | 5.8  | 64 |
| 203 | Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 2130-8  | 15.1 | 58 |
| 202 | Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. <i>Circulation</i> , <b>2020</b> , 141, e779-e806   | 16.7 | 58 |
| 201 | Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1983-1987          | 6.7  | 55 |
| 200 | Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. <i>Thrombosis Research</i> , <b>2012</b> , 129, 32-5   | 8.2  | 54 |
| 199 | Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , <b>2020</b> , 142, 1040-1054  | 16.7 | 52 |
| 198 | The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , <b>2013</b> , 61, S12-23 | 7.4  | 51 |
| 197 | Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. <i>Circulation</i> , <b>2014</b> , 129, 1303-9   | 16.7 | 50 |
| 196 | Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. <i>Lancet Diabetes and Endocrinology</i> , <b>2015</b> , 3, 876-85  | 18.1 | 48 |
| 195 | Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , <b>2019</b> , 140, 618-620  | 16.7 | 46 |

|     |   |      |    |
|-----|---|------|----|
| 194 | Glucose management in critically ill adults and children. <i>Lancet Diabetes and Endocrinology</i> , <b>2015</b> , 3, 723-33  | 18.1 | 43 |
| 193 | Association of door-to-balloon time and mortality in patients > or =65 years with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>American Journal of Cardiology</i> , <b>2009</b> , 104, 1198-203         | 3    | 43 |
| 192 | Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. <i>Reviews in Cardiovascular Medicine</i> , <b>2014</b> , 15, 11-23   | 3.9  | 42 |
| 191 | Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. <i>Endocrine Practice</i> , <b>2013</b> , 19, 81-90  | 3.2  | 41 |
| 190 | Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1577-8  | 59.2 | 40 |
| 189 | Serum complement activation in congestive heart failure. <i>American Heart Journal</i> , <b>2001</b> , 141, 684-90  | 4.9  | 40 |
| 188 | Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , <b>2020</b> , 41, 3402-3418 <sup>40</sup>               | 9.5  | 40 |
| 187 | Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1337-1341 | 6.7  | 39 |
| 186 | Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1217-1225   | 12.3 | 39 |
| 185 | Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus. <i>Circulation</i> , <b>2019</b> , 139, 730-743   | 16.7 | 39 |
| 184 | 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022.. <i>Diabetes Care</i> , <b>2022</b> , 45, S83-S96  | 14.6 | 39 |
| 183 | Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 799-807                            | 18.1 | 38 |
| 182 | Age at diagnosis predicts deterioration in glycaemic control among children and adolescents with type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , <b>2014</b> , 2, e000039   | 4.5  | 38 |
| 181 | Relation of anemia at discharge to survival after acute coronary syndromes. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 496-9   | 3    | 38 |
| 180 | Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 586-594                    | 18.1 | 38 |
| 179 | Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 1188-1196    | 3.2  | 37 |
| 178 | Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 606-615  | 18.1 | 37 |
| 177 | Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2836-2850   | 15.1 | 36 |

|     |  |      |    |
|-----|--|------|----|
| 176 | Predictors of Physician Under-Recognition of Angina in Outpatients With Stable Coronary Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2016</b> , 9, 554-9   | 5.8  | 35 |
| 175 | Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial. <i>Circulation</i> , <b>2021</b> , 143, 1673-1686  | 16.7 | 35 |
| 174 | Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 499-507   | 16.2 | 35 |
| 173 | Use of Intensive Glycemic Management in Older Adults with Diabetes Mellitus. <i>Journal of the American Geriatrics Society</i> , <b>2018</b> , 66, 1190-1194   | 5.6  | 34 |
| 172 | Effect of glucose-lowering therapies on heart failure. <i>Nature Reviews Cardiology</i> , <b>2018</b> , 15, 282-291  | 14.8 | 34 |
| 171 | Practice-Level Variation in Statin Use Among Patients With Diabetes: Insights From the PINNACLE Registry. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 1368-9  | 15.1 | 34 |
| 170 | Diabetes mellitus and trends in hospital survival after myocardial infarction, 1994 to 2006: data from the national registry of myocardial infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2012</b> , 5, 791-7  | 5.8  | 34 |
| 169 | Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease. <i>American Heart Journal</i> , <b>2017</b> , 184, 114-120  | 4.9  | 33 |
| 168 | Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non-ST Elevation Myocardial Infarction: Insights From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines (NCDR ACTION Registry-GWTG). <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2019</b> , 12, e007037 | 5.8  | 33 |
| 167 | Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , <b>2019</b> , 151, 20-32  | 7.4  | 31 |
| 166 | Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 389-399   | 6.7  | 31 |
| 165 | Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , <b>2019</b> , 25, 584-619   | 3.3  | 30 |
| 164 | Blood transfusion during acute myocardial infarction: association with mortality and variability across hospitals. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 811-9  | 15.1 | 30 |
| 163 | Glucose variability and mortality in patients hospitalized with acute myocardial infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2012</b> , 5, 550-7  | 5.8  | 30 |
| 162 | Predictors of weight change in overweight patients with myocardial infarction. <i>American Heart Journal</i> , <b>2007</b> , 154, 711-7  | 4.9  | 30 |
| 161 | Performance of the Medtronic Sentrino continuous glucose management (CGM) system in the cardiac intensive care unit. <i>BMJ Open Diabetes Research and Care</i> , <b>2014</b> , 2, e000037   | 4.5  | 29 |
| 160 | The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. <i>Nature Medicine</i> , <b>2021</b> , 27, 1954-1960  | 50.5 | 29 |
| 159 | Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. <i>American Heart Journal</i> , <b>2017</b> , 189, 158-166   | 4.9  | 27 |

|     |  |      |    |
|-----|--|------|----|
| 158 | Discontinuation of antihyperglycemic therapy and clinical outcomes after acute myocardial infarction in older patients with diabetes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2010</b> , 3, 236-42        | 5.8  | 27 |
| 157 | Glucose-lowering targets for patients with cardiovascular disease: focus on inpatient management of patients with acute coronary syndromes. <i>Circulation</i> , <b>2010</b> , 122, 2736-44                                    | 16.7 | 27 |
| 156 | Blood glucose and its prognostic implications in patients hospitalised with acute myocardial infarction. <i>Diabetes and Vascular Disease Research</i> , <b>2008</b> , 5, 269-75   | 3.3  | 27 |
| 155 | Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 858-65   | 2.4  | 27 |
| 154 | The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.. <i>Nature Medicine</i> , <b>2022</b> ,  | 50.5 | 27 |
| 153 | Usefulness of myocardial contrast echocardiography in predicting late mortality in patients with anterior wall acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2006</b> , 98, 1150-5                   | 3    | 26 |
| 152 | Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 867-874   | 14.6 | 26 |
| 151 | Real World Evidence for Treatment of Hyperkalemia in the Emergency Department (REVEAL-ED): A Multicenter, Prospective, Observational Study. <i>Journal of Emergency Medicine</i> , <b>2018</b> , 55, 741-750                   | 1.5  | 26 |
| 150 | Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 1215-1221  | 3.2  | 25 |
| 149 | Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 1216-1227             | 9.5  | 25 |
| 148 | Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1121-1127              | 6.7  | 25 |
| 147 | Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. <i>Diabetes Care</i> , <b>2021</b> , 44, 586-594                        | 14.6 | 24 |
| 146 | Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry. <i>Diabetes Care</i> , <b>2016</b> , 39, e99-e101                             | 14.6 | 23 |
| 145 | Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 826-834 | 12.3 | 23 |
| 144 | Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 254-264   | 7.9  | 23 |
| 143 | Elevations of metabolic risk factors 20 years or more before diagnosis of type 2 diabetes: Experience from the AMORIS study. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1419-1426                             | 6.7  | 22 |
| 142 | Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , <b>2021</b> , 42, 3727-3738   | 9.5  | 22 |
| 141 | Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized With Non-ST-Segment Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 36-44  | 16.2 | 21 |



|     |   |      |    |
|-----|---|------|----|
| 140 | Association between hyperglycemia at admission during hospitalization for acute myocardial infarction and subsequent diabetes: insights from the veterans administration cardiac care follow-up clinical study. <i>Diabetes Care</i> , <b>2014</b> , 37, 409-18 | 14.6 | 21 |
| 139 | Self-reported use of complementary and alternative medicine in patients with previous acute coronary syndrome. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 930-3  | 3    | 21 |
| 138 | Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2000-2003  | 6.7  | 20 |
| 137 | Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. <i>Circulation</i> , <b>2020</b> , 142, 1623-1632   | 16.7 | 20 |
| 136 | Understanding Contemporary Use of Thiazolidinediones. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005855   | 7.6  | 19 |
| 135 | Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1247-1258  | 12.3 | 19 |
| 134 | Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2474-2485                       | 6.7  | 19 |
| 133 | Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1926-1942   | 15.1 | 19 |
| 132 | Association of longitudinal measures of hemoglobin and outcomes after hospitalization for heart failure. <i>American Heart Journal</i> , <b>2010</b> , 159, 81-9  | 4.9  | 19 |
| 131 | Relationship between glycosylated hemoglobin assessment and glucose therapy intensification in patients with diabetes hospitalized for acute myocardial infarction. <i>Diabetes Care</i> , <b>2012</b> , 35, 991-3  | 14.6 | 19 |
| 130 | New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. <i>International Journal of Cardiology</i> , <b>2016</b> , 216, 46-51                        | 3.2  | 19 |
| 129 | Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 886-896          | 6.7  | 19 |
| 128 | Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Diabetes: Insights From the OPEN CTO Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2017</b> , 10, 2174-2181 <sup>5</sup>                                     |      | 18 |
| 127 | Admission body temperature and mortality in elderly patients hospitalized for heart failure. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 2563-4  | 15.1 | 18 |
| 126 | Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials. <i>Journal of General Internal Medicine</i> , <b>2017</b> , 32, 1044-1051   | 4    | 17 |
| 125 | Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE. <i>American Journal of Nephrology</i> , <b>2019</b> , 50, 473-480   | 4.6  | 17 |
| 124 | Predicting Adverse Outcomes After Myocardial Infarction Among Patients With Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2016</b> , 9, 372-9   | 5.8  | 17 |
| 123 | Recovery from hospital-acquired anemia after acute myocardial infarction and effect on outcomes. <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 949-54  | 3    | 17 |

|     |  |      |    |
|-----|--|------|----|
| 122 | Usefulness of left ventricular diastolic dysfunction as a predictor of one-year rehospitalization in survivors of acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2009</b> , 103, 17-21  | 3    | 17 |
| 121 | Assessment of right ventricular morphology and function. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2003</b> , 24, 245-62  | 3.9  | 17 |
| 120 | The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , <b>2021</b> ,  | 9.5  | 17 |
| 119 | Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21 Suppl 2, 19-23  | 6.7  | 16 |
| 118 | Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. <i>American Journal of Cardiology</i> , <b>2009</b> , 104, 910-6  | 3    | 16 |
| 117 | Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. <i>Circulation</i> , <b>2020</b> , 142, 1205-1218  | 16.7 | 16 |
| 116 | Importance of measuring glycosylated hemoglobin in patients with myocardial infarction and known diabetes mellitus. <i>American Journal of Cardiology</i> , <b>2010</b> , 105, 1090-4  | 3    | 15 |
| 115 | Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). <i>American Heart Journal</i> , <b>2018</b> , 203, 25-29  | 4.9  | 15 |
| 114 | Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 567-73  | 5.5  | 14 |
| 113 | Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,  | 6    | 14 |
| 112 | Use of an Intravascular Fluorescent Continuous Glucose Sensor in ICU Patients. <i>Journal of Diabetes Science and Technology</i> , <b>2015</b> , 9, 762-70   | 4.1  | 14 |
| 111 | Outcomes associated with anemia in patients with heart failure. <i>Heart Failure Clinics</i> , <b>2010</b> , 6, 359-72   | 3.3  | 14 |
| 110 | Effect of dapagliflozin on anaemia in DAPA-HF. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 617-628  | 12.3 | 14 |
| 109 | Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 601-613   | 12.3 | 14 |
| 108 | Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> , 36, 137-150 | 4.3  | 14 |
| 107 | Hypoglycemia and adverse outcomes: marker or mediator?. <i>Reviews in Cardiovascular Medicine</i> , <b>2011</b> , 12, 132-5  | 3.9  | 14 |
| 106 | Serum Magnesium Levels and In-Hospital Mortality in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2771-2772  | 15.1 | 13 |
| 105 | Recognition of incident diabetes mellitus during an acute myocardial infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2015</b> , 8, 260-7  | 5.8  | 13 |

|     |  |      |    |
|-----|--|------|----|
| 104 | Hyperglycemia in Acute Coronary Syndromes: From Mechanisms to Prognostic Implications. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2018</b> , 47, 185-202  | 5.5  | 13 |
| 103 | Effects of ranolazine on quality of life among patients with diabetes mellitus and stable angina. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 1403-5  | 11.5 | 13 |
| 102 | Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , <b>2021</b> , 143, 1962-1972  | 16.7 | 13 |
| 101 | Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. <i>Circulation</i> , <b>2019</b> , 140, 2108-2118       | 16.7 | 13 |
| 100 | Potential New Agents for the Management of Hyperkalemia. <i>American Journal of Cardiovascular Drugs</i> , <b>2016</b> , 16, 19-31   | 4    | 12 |
| 99  | Advances in CKD detection and determination of prognosis: executive summary of the National Kidney Foundation-Kidney Early Evaluation Program (KEEP) 2012 annual data report. <i>American Journal of Kidney Diseases</i> , <b>2013</b> , 61, S1-3                  | 7.4  | 12 |
| 98  | The reliability and prognosis of in-hospital diagnosis of metabolic syndrome in the setting of acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 704-8   | 15.1 | 12 |
| 97  | Piloting a novel algorithm for glucose control in the coronary care unit: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) trial. <i>Diabetes Care</i> , <b>2012</b> , 35, 19-24  | 14.6 | 12 |
| 96  | The relationship between anemia, change in hematocrit over time and change in health status in patients with heart failure after myocardial infarction. <i>Journal of Cardiac Failure</i> , <b>2008</b> , 14, 27-34  | 3.3  | 12 |
| 95  | Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1985-1989          | 6.7  | 11 |
| 94  | Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c. <i>American Heart Journal</i> , <b>2014</b> , 168, 457-465.e2  | 4.9  | 11 |
| 93  | An overview of glycemic control in the coronary care unit with recommendations for clinical management. <i>Journal of Diabetes Science and Technology</i> , <b>2009</b> , 3, 1342-51   | 4.1  | 11 |
| 92  | Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus. <i>American Journal of Nephrology</i> , <b>2020</b> , 51, 74-82   | 4.6  | 11 |
| 91  | Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2364-2374 | 6.7  | 11 |
| 90  | Long COVID - metabolic risk factors and novel therapeutic management. <i>Nature Reviews Endocrinology</i> , <b>2021</b> , 17, 379-380  | 15.2 | 11 |
| 89  | Are We Ready to Bell The Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes. <i>Circulation</i> , <b>2018</b> , 138, 4-6  | 16.7 | 11 |
| 88  | Red blood cell indices and development of hospital-acquired anemia during acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 1104-10  | 3    | 10 |
| 87  | High hemoglobin A1c variability is associated with early risk of microalbuminuria in children with T1D. <i>Pediatric Diabetes</i> , <b>2016</b> , 17, 398-406  | 3.6  | 9  |

|    |   |      |   |
|----|---|------|---|
| 86 | Patterns and predictors of intensive statin therapy among patients with diabetes mellitus after acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1267-72   | 3    | 9 |
| 85 | Association between diabetes mellitus and angina after acute myocardial infarction: analysis of the TRIUMPH prospective cohort study. <i>European Journal of Preventive Cardiology</i> , <b>2015</b> , 22, 779-87   | 3.9  | 9 |
| 84 | Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. <i>American Heart Journal</i> , <b>2020</b> , 219, 70-77                | 4.9  | 9 |
| 83 | Newly Discovered Abnormal Glucose Tolerance in Patients With Acute Myocardial Infarction and Cardiovascular Outcomes: A Meta-analysis. <i>Diabetes Care</i> , <b>2020</b> , 43, 1958-1966   | 14.6 | 9 |
| 82 | Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1085-1093  | 12.3 | 9 |
| 81 | Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. <i>American Heart Journal</i> , <b>2016</b> , 182, 111-118  | 4.9  | 9 |
| 80 | A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. <i>Kidney International</i> , <b>2021</b> ,                                       | 9.9  | 9 |
| 79 | Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 66-78  | 6.7  | 8 |
| 78 | Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. <i>Diabetes Care</i> , <b>2020</b> , 43, 2878-2881   | 14.6 | 8 |
| 77 | A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. <i>American Journal of Cardiology</i> , <b>2019</b> , 124 Suppl 1, S12-S19  | 3    | 8 |
| 76 | Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? <i>Diabetes Care</i> 2018;41:6-10. <i>Diabetes Care</i> , <b>2018</b> , 41, e106-e108  | 14.6 | 8 |
| 75 | Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2349-2353   | 6.7  | 7 |
| 74 | Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e007879  | 7.6  | 7 |
| 73 | Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications. <i>Cardiovascular Endocrinology and Metabolism</i> , <b>2020</b> , 9, 56-59 | 2.5  | 7 |
| 72 | Glycemic Control, Renal Complications, and Current Smoking in Relation to Excess Risk of Mortality in Persons With Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , <b>2016</b> , 10, 1006-14   | 4.1  | 7 |
| 71 | The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarction. <i>BMJ Open Diabetes Research and Care</i> , <b>2014</b> , 2, e000046   | 4.5  | 7 |
| 70 | Changes in low-density lipoprotein cholesterol levels after discharge for acute myocardial infarction in a real-world patient population. <i>American Journal of Epidemiology</i> , <b>2014</b> , 179, 1293-300   | 3.8  | 7 |
| 69 | Two Tales: One Story: EMPEROR-Reduced and DAPA-HF. <i>Circulation</i> , <b>2020</b> , 142, 2201-2204  | 16.7 | 7 |

|    |  |      |   |
|----|--|------|---|
| 68 | Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 678-689   | 16.2 | 7 |
| 67 | The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. <i>International Journal of Cardiology</i> , <b>2020</b> , 318, 126-129  | 3.2  | 6 |
| 66 | Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)". <i>Circulation</i> , <b>2018</b> , 137, 989-991 | 16.7 | 6 |
| 65 | Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 261-266  | 6.7  | 6 |
| 64 | Sources of hospital-level variation in major bleeding among patients with non-st-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry (NCDR). <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2014</b> , 7, 236-43  | 5.8  | 6 |
| 63 | Residual Angina After Elective Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2017</b> , 10,  | 5.8  | 6 |
| 62 | Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 517-519   | 3.2  | 6 |
| 61 | Variation in the incidence of hospital-acquired anemia during hospitalization with acute myocardial infarction (data from 57 US hospitals). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1130-6  | 3    | 6 |
| 60 | Type 2 diabetes and heart failure: insights from the global DISCOVER study. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 1711-1716  | 3.7  | 6 |
| 59 | Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1662-1672   | 12.3 | 6 |
| 58 | A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. <i>IScience</i> , <b>2021</b> , 24, 103040   | 6.1  | 6 |
| 57 | Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial. <i>American Heart Journal</i> , <b>2015</b> , 170, 753-759.e2  | 4.9  | 5 |
| 56 | Careers in cardiovascular outcomes research. <i>Circulation</i> , <b>2009</b> , 120, 76-81   | 16.7 | 5 |
| 55 | Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1426-1430  | 6.7  | 5 |
| 54 | Cardiac Autoimmunity Is Associated With Subclinical Myocardial Dysfunction in Patients With Type 1 Diabetes Mellitus. <i>Circulation</i> , <b>2020</b> , 141, 1107-1109  | 16.7 | 5 |
| 53 | Study design of Real World Evidence for Treatment of Hyperkalemia in the Emergency Department (REVEAL-ED): a multicenter, prospective, observational study. <i>Clinical and Experimental Emergency Medicine</i> , <b>2017</b> , 4, 154-159   | 1.7  | 4 |
| 52 | Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study. <i>American Heart Journal</i> , <b>2022</b> , 243, 232-239  | 4.9  | 4 |
| 51 | Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1431-1435   | 6.7  | 4 |

|    |  |      |   |
|----|--|------|---|
| 50 | Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes. <i>Diabetes Care</i> , <b>2021</b> , 44, 1499-1505   | 14.6 | 4 |
| 49 | Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 2603-2607  | 3.7  | 4 |
| 48 | Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea). <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 455-466            | 6.7  | 4 |
| 47 | Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 39-48                   | 6.7  | 4 |
| 46 | THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW. <i>Endocrine Practice</i> , <b>2017</b> , 23, 363-371  | 3.2  | 3 |
| 45 | New frontiers for management of hyperkalaemia: the emergence of novel agents. <i>European Heart Journal Supplements</i> , <b>2019</b> , 21, A34-A40  | 1.5  | 3 |
| 44 | Regional differences in the management of cardiovascular risk factors among adults with diabetes: An evaluation of the Diabetes Collaborative Registry. <i>Journal of Diabetes and Its Complications</i> , <b>2020</b> , 34, 107591  | 3.2  | 3 |
| 43 | Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , <b>2020</b> , 165, 108230                        | 7.4  | 3 |
| 42 | Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy. <i>European Heart Journal</i> , <b>2018</b> , 39, 193-200  | 9.5  | 3 |
| 41 | Gender differences in the association between discharge hemoglobin and 12-month mortality after acute myocardial infarction. <i>Clinical Cardiology</i> , <b>2017</b> , 40, 1279-1284  | 3.3  | 3 |
| 40 | Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> ,                   | 18.1 | 3 |
| 39 | Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 159 | 8.7  | 3 |
| 38 | Adherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction. <i>JAMA Network Open</i> , <b>2020</b> , 3, e203032                   | 10.4 | 3 |
| 37 | Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). <i>Journal of Diabetes and Its Complications</i> , <b>2018</b> , 32, 1035-1039                            | 3.2  | 2 |
| 36 | Temporal trends and hospital variation in the management of severe hyperglycemia among patients with acute myocardial infarction in the United States. <i>American Heart Journal</i> , <b>2013</b> , 166, 315-324.e1                 | 4.9  | 2 |
| 35 | Hospitalization for Heart Failure and Death in New Users of SGLT-2 Inhibitors in Patients With and Without Cardiovascular Disease—CVD Real Study. <i>Canadian Journal of Diabetes</i> , <b>2017</b> , 41, S51-S52                    | 2.1  | 2 |
| 34 | Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal. <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 1451-1457  | 3.2  | 2 |
| 33 | Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2366-2377  | 15.1 | 2 |

|    |  |      |   |
|----|--|------|---|
| 32 | Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1956-1960  | 6.7  | 2 |
| 31 | Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 1298-1305 | 16.2 | 2 |
| 30 | The Association Between Complementary and Alternative Medicine and Health Status Following Acute Myocardial Infarction. <i>Clinical Cardiology</i> , <b>2016</b> , 39, 440-5   | 3.3  | 2 |
| 29 | Sodium-glucose cotransporter $\text{2}$ inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study. <i>Journal of Diabetes Investigation</i> , <b>2021</b> , 12, 67-73  | 3.9  | 2 |
| 28 | Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 139   | 8.7  | 2 |
| 27 | Patient characteristics and acute cardiovascular event rates among patients with very high-risk and non-very high-risk atherosclerotic cardiovascular disease. <i>Clinical Cardiology</i> , <b>2021</b> , 44, 1457-1466                                      | 3.3  | 2 |
| 26 | Cardiometabolic Center of Excellence: A Novel Care Delivery Model for Secondary Prevention of Cardiovascular Disease in Type 2 Diabetes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2021</b> , 14, e007682                                 | 5.8  | 2 |
| 25 | Hospital variability in use of anticoagulant strategies during acute myocardial infarction treated with an early invasive strategy. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4, e002009  | 6    | 1 |
| 24 | A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. <i>American Journal of Medicine</i> , <b>2019</b> , 132, S13-S20   | 2.4  | 1 |
| 23 | Reply: In regard to the TERISA trial. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 420-1   | 15.1 | 1 |
| 22 | Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , <b>2021</b> ,                                   | 16.7 | 1 |
| 21 | Association Between Change in Ambulatory Hemodynamic Pressures and Symptoms of Heart Failure. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008446  | 7.6  | 1 |
| 20 | Use of non-LDL-C lipid-lowering medications in patients with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , <b>2020</b> , 3, e00126  | 2.7  | 1 |
| 19 | Methods and rationale of the DISCOVER CKD global observational study. <i>CKJ: Clinical Kidney Journal</i> , <b>2021</b> , 14, 1570-1578  | 4.5  | 1 |
| 18 | Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence. <i>Journal of Heart and Lung Transplantation</i> , <b>2021</b> , 40, 426-429         | 5.8  | 1 |
| 17 | Novel Trial Design: CHIEF-HF. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e007767  | 7.6  | 1 |
| 16 | Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 177, 108870   | 7.4  | 1 |
| 15 | Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 180, 108974  | 7.4  | 1 |

|    |   |      |   |
|----|---|------|---|
| 14 | Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. <i>Cardiovascular Diabetology</i> , <b>2022</b> , 21, 50   | 8.7  | 1 |
| 13 | Real-world opportunity of empagliflozin to improve blood pressure control in African American patients with type 2 diabetes: A National Cardiovascular Data Registry "research-to-practice" project from the diabetes collaborative registry. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 393-396 | 6.7  | 0 |
| 12 | Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study.. <i>Diabetes Research and Clinical Practice</i> , <b>2022</b> , 185, 109218  | 7.4  | 0 |
| 11 | Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 108077                                       | 3.2  | 0 |
| 10 | Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme. <i>BMJ Open</i> , <b>2020</b> , 10, e034613   | 3    | 0 |
| 9  | What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e020893   | 6    | 0 |
| 8  | Response by Nassif and Kosiborod to Letter Regarding Article, "Are We Ready to Bell the Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes". <i>Circulation</i> , <b>2019</b> , 139, 305-306   | 16.7 |   |
| 7  | RESPONSE: The Imperative to Change the Delivery of Cardiometabolic Care: The Future Is Now. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 1236-1237  | 15.1 |   |
| 6  | Sodium-glucose co-transporter-2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: From efficacy to effectiveness. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 763-765   | 6.7  |   |
| 5  | Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus. <i>Annals of Internal Medicine</i> , <b>2017</b> , 167, 73-748  |      |   |
| 4  | Training programs in outcomes research: the "field guide" for current opportunities. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2009</b> , 2, 678-80  | 5.8  |   |
| 3  | Dapagliflozin in patients with COVID-19: mind the kidneys - AuthorsReply.. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> ,   | 18.1 |   |
| 2  | Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 1109-1110  | 3.3  |   |
| 1  | Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care. <i>Current Opinion in Cardiology</i> , <b>2020</b> , 35, 589-601  | 2.1  |   |